Timothy P. Clackson - 17 Feb 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.

Reporting relationship: President and CEO, Director
Issuer ticker: N/A
Reported as of: 17 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Feb 2023, 06:00:26 UTC
Prior SEC filing: 14 Nov 2022
Next SEC filing: 02 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Bradford Dahms - Attorney-in-Fact

Key filing fact

Timothy P. Clackson filed Form 4 for Theseus Pharmaceuticals, Inc. on 21 Feb 2023.

Key facts

This page summarizes Timothy P. Clackson's Form 4 filing for Theseus Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Feb 2023, 06:00.

Change

Previous filing in this sequence was filed on 14 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

THRX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +273,750
Change %
Price: $0.000000
Shares after: 273,750
Date: 17 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 273,750
Exercise price: $11.42
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 17, 2024 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer.